RYSTIGGO® (rizsteglib) is a medication approved for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody-positive [1].
How can I get a discount or savings on Rystiggo?
Patients may be eligible for savings programs offered by the manufacturer, UCB. The UCB SAVINGS PROGRAM for RYZSTIGGO is designed to help reduce out-of-pocket costs for eligible commercially insured patients [2]. Information regarding eligibility and how to enroll in this program can be found on the official Rystiggo website or through patient support services [2]. For those without commercial insurance, other assistance programs may be available [3].
What is Rystiggo used for?
RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies [1].
How does Rystiggo work?
Rystiggo is a neonatal Fc receptor (FcRn) antagonist. By blocking FcRn, it reduces the levels of disease-associated immunoglobulin G (IgG) antibodies, including anti-AChR antibodies, which contribute to the autoimmune attack in gMG [4].
What is the clinical data supporting Rystiggo's approval?
Rystiggo's approval was based on clinical trials demonstrating its efficacy in improving symptoms of gMG. In the Phase 3 MYKTAZIA trial, Rystiggo showed statistically significant improvements in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) score compared to placebo in patients with AChR+ gMG [4].
When does the patent for Rystiggo expire?
Information regarding the patent expiry for Rystiggo is available through specialized resources. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate when market exclusivity is expected to end [5].
Are there other treatments for generalized myasthenia gravis?
Yes, several other treatment options exist for gMG, depending on the patient's antibody status and disease severity. These can include immunosuppressants, corticosteroids, and other therapies aimed at managing symptoms and underlying autoimmune processes [1][4].
Who manufactures Rystiggo?
Rystiggo is manufactured by UCB [2].
What are the potential side effects of Rystiggo?
Common side effects reported in clinical trials include [1]:
* Headache
* Diarrhea
* Nausea
* Vomiting
* Fatigue
* Muscle spasms
* Shortness of breath
* Infections of the upper respiratory tract
* Joint pain
* Dizziness
* Rash
Serious side effects may also occur, and patients should discuss any concerns with their healthcare provider [1].
---
Sources:
1. https://www.rystiggo.com/
2. https://www.rystiggo.com/savings-and-support
3. https://www.rystiggo.com/savings-and-support/patient-assistance-program
4. https://www.ucb.com/stories-detail/UCB-announces-US-FDA-approval-of-RYSTIGGO%C2%AE-rizsteglib-a-first-in-class-treatment-for-generalized-myasthenia-gravis-in-adults-who-are-anti-acetylcholine-receptor-antibody-positive
5. https://drugpatentwatch.com/